Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.57 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.38 |
| ▸ | FNTA | P49354 | 1/20 | 0.33 |
| ▸ | FNTB | P49356 | 1/20 | 0.33 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3055805 | 1.00 | ALDH1A1 (0.57) | ALDH1A1ALOX15PTPN1LMNAHSD17B10 | |
| SCHEMBL5245886 | 1.00 | ALDH1A1 (0.57) | ALDH1A1ALOX15PTPN1LMNAHSD17B10 | |
| SCHEMBL16485592 | 0.89 | ALDH1A1 (0.71) | ALDH1A1ALOX15PTPN1FNTAFNTB | |
| SCHEMBL381050 | 0.89 | ALDH1A1 (0.71) | ALDH1A1ALOX15PTPN1FNTAFNTB | |
| SCHEMBL16673068 | 0.89 | ALDH1A1 (0.71) | ALDH1A1ALOX15PTPN1FNTAFNTB | |
| SCHEMBL11806001 | 0.89 | ALDH1A1 (0.71) | ALDH1A1ALOX15PTPN1FNTAFNTB | |
| SCHEMBL8620391 | 0.89 | ALDH1A1 (0.71) | ALDH1A1ALOX15PTPN1FNTAFNTB | |
| SCHEMBL381049 | 0.89 | ALDH1A1 (0.71) | ALDH1A1ALOX15PTPN1FNTAFNTB | |
| SCHEMBL11805997 | 0.89 | ALDH1A1 (0.71) | ALDH1A1ALOX15PTPN1FNTAFNTB | |
| SCHEMBL7705366 | 0.80 | ALDH1A1 (0.47) | ALDH1A1ALOX15PTPN1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110240543-B | Preparation method of 4-bromo-3-methyl-2-buten-1-ol acetate | 南京瑞鼎生物医药有限公司 | 2022-02-01 | — | — | CN | claimed |
| US-4175204-A | Method of preparing E-4-acetoxy-2-methyl-2-butenal | BABLER JAMES H | 1979-11-20 | — | — | US | claimed |
| CN-111484407-B | Preparation method of 1-halogenated-2-methyl-4-substituted carbonyloxy-2-butene | 新发药业有限公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-111484524-B | Vitamin A acetate intermediate C15 and preparation method of vitamin A acetate | 新发药业有限公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-110240543-B | Preparation method of 4-bromo-3-methyl-2-buten-1-ol acetate | 南京瑞鼎生物医药有限公司 | 2022-02-01 | — | — | CN | disclosed |
| CN-110240543-B | Preparation method of 4-bromo-3-methyl-2-buten-1-ol acetate | 南京瑞鼎生物医药有限公司 | 2022-02-01 | — | — | CN | disclosed |
| CN-110240543-B | Preparation method of 4-bromo-3-methyl-2-buten-1-ol acetate | 南京瑞鼎生物医药有限公司 | 2022-02-01 | — | — | CN | disclosed |
| CN-111484407-A | Preparation method of 1-halogenated-2-methyl-4-substituted carbonyloxy-2-butene | 新发药业有限公司 | 2020-08-04 | — | — | CN | disclosed |
| CN-111484524-A | Vitamin A acetate intermediate C15 and preparation method of vitamin A acetate | 新发药业有限公司 | 2020-08-04 | — | — | CN | disclosed |
| US-20100222306-A1 | Class of Gamma Delta T Cells Activators and Use Thereof | INNATE PHARMA, S.A. (FR) | 2010-09-02 | — | — | US | disclosed |
| US-7683045-B2 | Class of γδ T cells activators and use thereof | INNATE PHARMA S.A. (FR) | 2010-03-23 | — | — | US | disclosed |
| US-20020107422-A1 | Process for producing allyl halide compound | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2002-08-08 | — | — | US | disclosed |
| EP-0670300-B1 | Process for the preparation of allyl quinone derivatives, and intermediates | EISAI CO LTD (JP) | 1999-06-23 | — | — | EP | disclosed |
| US-5874611-A | Butenyl hydroquinone derivatives | EISAI CHEMICAL CO., LTD. (JP) | 1999-02-23 | — | — | US | disclosed |
| US-5565586-A | Oxidative process for the preparation of allyl quinone derivatives | EISAI CHEMICAL CO., LTD. (JP) | 1996-10-15 | — | — | US | disclosed |
| EP-0670300-A2 | Process for the preparation of allyl quinone derivatives, and intermediates | EISAI CHEMICAL CO., LTD. (JP) | 1995-09-06 | — | — | EP | disclosed |
| EP-0008581-A1 | METHOD OF PREPARING E-4-ACETOXY-2-METHYL-2-BUTENAL | BABLER, James, H. (US) | 1980-03-05 | — | — | EP | disclosed |
| US-4175204-A | Method of preparing E-4-acetoxy-2-methyl-2-butenal | BABLER JAMES H | 1979-11-20 | — | — | US | disclosed |
| WO-1979000485-A1 | METHOD OF PREPARING E-4-ACETOXY-2-METHYL-2-BUTENAL | BABLER J | 1979-07-26 | — | — | WO | disclosed |
| US-3957836-A | QUINONE DERIVATIVES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JA) | 1976-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222306-A1 | Class of Gamma Delta T Cells Activators and Use Thereof | NFATC1, CD4, CD74 | ALDH1A1 1830/4885ALOX15 1278/4885PTPN1 351/4885 |
| US-20020107422-A1 | Process for producing allyl halide compound | ENY2, ZYX, RPS4Y1 | ALDH1A1 1133/4885ALOX15 103/4885PTPN1 3173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.